25 XP   0   0   10

Xvivo Perfusion AB
Buy, Hold or Sell?

Let's analyse Xvivo Perfusion AB together

PenkeI guess you are interested in Xvivo Perfusion AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Xvivo Perfusion AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Xvivo Perfusion AB

I send you an email if I find something interesting about Xvivo Perfusion AB.

Quick analysis of Xvivo Perfusion AB (30 sec.)










What can you expect buying and holding a share of Xvivo Perfusion AB? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
kr61.75
Expected worth in 1 year
kr127.13
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
kr65.39
Return On Investment
17.5%

For what price can you sell your share?

Current Price per Share
kr373.00
Expected price per share
kr294.00 - kr
How sure are you?
50%

1. Valuation of Xvivo Perfusion AB (5 min.)




Live pricePrice per Share (EOD)

kr373.00

Intrinsic Value Per Share

kr-39.52 - kr-23.72

Total Value Per Share

kr22.22 - kr38.03

2. Growth of Xvivo Perfusion AB (5 min.)




Is Xvivo Perfusion AB growing?

Current yearPrevious yearGrowGrow %
How rich?$177.7m$130.7m$47m26.5%

How much money is Xvivo Perfusion AB making?

Current yearPrevious yearGrowGrow %
Making money$8.3m$1.6m$6.7m79.9%
Net Profit Margin15.4%4.4%--

How much money comes from the company's main activities?

3. Financial Health of Xvivo Perfusion AB (5 min.)




4. Comparing to competitors in the Medical Devices industry (5 min.)




  Industry Rankings (Medical Devices)  


Richest
#109 / 334

Most Revenue
#167 / 334

Most Profit
#84 / 334

What can you expect buying and holding a share of Xvivo Perfusion AB? (5 min.)

Welcome investor! Xvivo Perfusion AB's management wants to use your money to grow the business. In return you get a share of Xvivo Perfusion AB.

What can you expect buying and holding a share of Xvivo Perfusion AB?

First you should know what it really means to hold a share of Xvivo Perfusion AB. And how you can make/lose money.

Speculation

The Price per Share of Xvivo Perfusion AB is kr373.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xvivo Perfusion AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xvivo Perfusion AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr61.75. Based on the TTM, the Book Value Change Per Share is kr16.35 per quarter. Based on the YOY, the Book Value Change Per Share is kr4.59 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xvivo Perfusion AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.270.1%0.270.1%0.050.0%0.050.0%0.030.0%
Usd Book Value Change Per Share1.490.4%1.490.4%0.420.1%0.820.2%0.540.1%
Usd Dividend Per Share0.000.0%0.000.0%0.020.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.490.4%1.490.4%0.440.1%0.820.2%0.540.1%
Usd Price Per Share30.12-30.12-16.73-23.31-15.37-
Price to Earnings Ratio113.04-113.04-312.82-472.01-565.57-
Price-to-Total Gains Ratio20.16-20.16-37.93-51.45-63.47-
Price to Book Ratio5.34-5.34-4.03-7.05-7.37-
Price-to-Total Gains Ratio20.16-20.16-37.93-51.45-63.47-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share34.0922
Number of shares29
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.490.82
Usd Total Gains Per Share1.490.82
Gains per Quarter (29 shares)43.3323.76
Gains per Year (29 shares)173.3195.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1017316309585
203473361189180
305205091284275
406936822378370
508678552473465
60104010283567560
70121312013662655
80138713744756750
90156015474851845
100173317205946940

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%10.02.01.076.9%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%13.00.00.0100.0%
Dividend per Share0.00.01.00.0%1.00.02.033.3%1.00.04.020.0%1.00.09.010.0%1.00.012.07.7%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%13.00.00.0100.0%

Fundamentals of Xvivo Perfusion AB

About Xvivo Perfusion AB

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Fundamental data was last updated by Penke on 2024-04-25 23:59:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Xvivo Perfusion AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xvivo Perfusion AB earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • A Net Profit Margin of 15.4% means that kr0.15 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Xvivo Perfusion AB:

  • The MRQ is 15.4%. The company is making a huge profit. +2
  • The TTM is 15.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ15.4%TTM15.4%0.0%
TTM15.4%YOY4.4%+10.9%
TTM15.4%5Y0.2%+15.2%
5Y0.2%10Y2.2%-2.0%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ15.4%-11.2%+26.6%
TTM15.4%-20.4%+35.8%
YOY4.4%-13.4%+17.8%
5Y0.2%-21.0%+21.2%
10Y2.2%-24.9%+27.1%
1.1.2. Return on Assets

Shows how efficient Xvivo Perfusion AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • 4.2% Return on Assets means that Xvivo Perfusion AB generated kr0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Xvivo Perfusion AB:

  • The MRQ is 4.2%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.2%TTM4.2%0.0%
TTM4.2%YOY1.1%+3.1%
TTM4.2%5Y0.6%+3.6%
5Y0.6%10Y1.1%-0.5%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2%-4.0%+8.2%
TTM4.2%-4.7%+8.9%
YOY1.1%-4.3%+5.4%
5Y0.6%-3.9%+4.5%
10Y1.1%-4.9%+6.0%
1.1.3. Return on Equity

Shows how efficient Xvivo Perfusion AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • 4.7% Return on Equity means Xvivo Perfusion AB generated kr0.05 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Xvivo Perfusion AB:

  • The MRQ is 4.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 4.7%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ4.7%TTM4.7%0.0%
TTM4.7%YOY1.3%+3.4%
TTM4.7%5Y0.6%+4.1%
5Y0.6%10Y1.2%-0.6%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7%-4.1%+8.8%
TTM4.7%-5.7%+10.4%
YOY1.3%-5.2%+6.5%
5Y0.6%-6.1%+6.7%
10Y1.2%-6.9%+8.1%

1.2. Operating Efficiency of Xvivo Perfusion AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xvivo Perfusion AB is operating .

  • Measures how much profit Xvivo Perfusion AB makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • An Operating Margin of 6.4% means the company generated kr0.06  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Xvivo Perfusion AB:

  • The MRQ is 6.4%. The company is operating less efficient.
  • The TTM is 6.4%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ6.4%TTM6.4%0.0%
TTM6.4%YOY5.6%+0.9%
TTM6.4%5Y-0.4%+6.8%
5Y-0.4%10Y2.9%-3.3%
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4%-24.3%+30.7%
TTM6.4%-16.7%+23.1%
YOY5.6%-13.7%+19.3%
5Y-0.4%-19.9%+19.5%
10Y2.9%-24.5%+27.4%
1.2.2. Operating Ratio

Measures how efficient Xvivo Perfusion AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Devices industry mean).
  • An Operation Ratio of 0.94 means that the operating costs are kr0.94 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 0.936. The company is less efficient in keeping operating costs low.
  • The TTM is 0.936. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.936TTM0.9360.000
TTM0.936YOY0.989-0.054
TTM0.9365Y1.034-0.098
5Y1.03410Y0.987+0.047
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9361.442-0.506
TTM0.9361.437-0.501
YOY0.9891.425-0.436
5Y1.0341.427-0.393
10Y0.9871.373-0.386

1.3. Liquidity of Xvivo Perfusion AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xvivo Perfusion AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Devices industry mean).
  • A Current Ratio of 6.14 means the company has kr6.14 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 6.145. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.145. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.145TTM6.1450.000
TTM6.145YOY3.466+2.679
TTM6.1455Y5.240+0.904
5Y5.24010Y5.568-0.328
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1452.691+3.454
TTM6.1452.724+3.421
YOY3.4663.496-0.030
5Y5.2403.619+1.621
10Y5.5683.487+2.081
1.3.2. Quick Ratio

Measures if Xvivo Perfusion AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • A Quick Ratio of 7.17 means the company can pay off kr7.17 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 7.171. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.171. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.171TTM7.1710.000
TTM7.171YOY2.601+4.571
TTM7.1715Y4.731+2.441
5Y4.73110Y4.576+0.155
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1711.503+5.668
TTM7.1711.663+5.508
YOY2.6012.142+0.459
5Y4.7312.307+2.424
10Y4.5762.313+2.263

1.4. Solvency of Xvivo Perfusion AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xvivo Perfusion AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xvivo Perfusion AB to Medical Devices industry mean.
  • A Debt to Asset Ratio of 0.11 means that Xvivo Perfusion AB assets are financed with 11.4% credit (debt) and the remaining percentage (100% - 11.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 0.114. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.114. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.114TTM0.1140.000
TTM0.114YOY0.175-0.061
TTM0.1145Y0.134-0.020
5Y0.13410Y0.113+0.021
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1140.402-0.288
TTM0.1140.390-0.276
YOY0.1750.335-0.160
5Y0.1340.442-0.308
10Y0.1130.460-0.347
1.4.2. Debt to Equity Ratio

Measures if Xvivo Perfusion AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • A Debt to Equity ratio of 12.9% means that company has kr0.13 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Xvivo Perfusion AB:

  • The MRQ is 0.129. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.129. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.129TTM0.1290.000
TTM0.129YOY0.212-0.083
TTM0.1295Y0.156-0.027
5Y0.15610Y0.129+0.027
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1290.562-0.433
TTM0.1290.564-0.435
YOY0.2120.480-0.268
5Y0.1560.622-0.466
10Y0.1290.685-0.556

2. Market Valuation of Xvivo Perfusion AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Xvivo Perfusion AB generates.

  • Above 15 is considered overpriced but always compare Xvivo Perfusion AB to the Medical Devices industry mean.
  • A PE ratio of 113.04 means the investor is paying kr113.04 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Xvivo Perfusion AB:

  • The EOD is 127.960. Based on the earnings, the company is expensive. -2
  • The MRQ is 113.037. Based on the earnings, the company is expensive. -2
  • The TTM is 113.037. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD127.960MRQ113.037+14.923
MRQ113.037TTM113.0370.000
TTM113.037YOY312.824-199.787
TTM113.0375Y472.010-358.972
5Y472.01010Y565.574-93.565
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD127.960-1.055+129.015
MRQ113.037-1.715+114.752
TTM113.037-2.213+115.250
YOY312.824-2.977+315.801
5Y472.010-2.300+474.310
10Y565.574-1.932+567.506
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Xvivo Perfusion AB:

  • The EOD is -120.322. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -106.290. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -106.290. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-120.322MRQ-106.290-14.032
MRQ-106.290TTM-106.2900.000
TTM-106.290YOY-55.916-50.373
TTM-106.2905Y-94.446-11.843
5Y-94.44610Y-164.217+69.770
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD-120.322-0.882-119.440
MRQ-106.290-1.612-104.678
TTM-106.290-3.213-103.077
YOY-55.916-6.238-49.678
5Y-94.446-5.513-88.933
10Y-164.217-5.292-158.925
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xvivo Perfusion AB is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Devices industry mean).
  • A PB ratio of 5.34 means the investor is paying kr5.34 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Xvivo Perfusion AB:

  • The EOD is 6.041. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.336. Based on the equity, the company is overpriced. -1
  • The TTM is 5.336. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.041MRQ5.336+0.704
MRQ5.336TTM5.3360.000
TTM5.336YOY4.031+1.305
TTM5.3365Y7.054-1.718
5Y7.05410Y7.370-0.315
Compared to industry (Medical Devices)
PeriodCompanyIndustry (mean)+/- 
EOD6.0412.025+4.016
MRQ5.3362.380+2.956
TTM5.3362.469+2.867
YOY4.0313.195+0.836
5Y7.0543.955+3.099
10Y7.3704.321+3.049
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Xvivo Perfusion AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--16.34716.3470%4.593+256%8.918+83%5.868+179%
Book Value Per Share--61.74861.7480%45.402+36%39.662+56%25.298+144%
Current Ratio--6.1456.1450%3.466+77%5.240+17%5.568+10%
Debt To Asset Ratio--0.1140.1140%0.175-35%0.134-15%0.113+1%
Debt To Equity Ratio--0.1290.1290%0.212-39%0.156-17%0.129+0%
Dividend Per Share----0%0.231-100%0.046-100%0.023-100%
Eps--2.9152.9150%0.585+398%0.505+477%0.346+743%
Free Cash Flow Per Share---3.100-3.1000%-3.273+6%-2.781-10%-1.629-47%
Free Cash Flow To Equity Per Share--10.18710.1870%-3.490+134%4.550+124%2.879+254%
Gross Profit Margin---1.530-1.5300%-7.270+375%-5.744+276%-7.058+361%
Intrinsic Value_10Y_max---23.721--------
Intrinsic Value_10Y_min---39.524--------
Intrinsic Value_1Y_max---1.794--------
Intrinsic Value_1Y_min---3.462--------
Intrinsic Value_3Y_max---5.835--------
Intrinsic Value_3Y_min---10.896--------
Intrinsic Value_5Y_max---10.412--------
Intrinsic Value_5Y_min---18.813--------
Market Cap11749313500.000+12%10379085250.00010379085250.0000%5764408500.000+80%8032372500.000+29%5297585910.000+96%
Net Profit Margin--0.1540.1540%0.044+246%0.002+8642%0.022+611%
Operating Margin--0.0640.0640%0.056+15%-0.004+106%0.029+120%
Operating Ratio--0.9360.9360%0.989-5%1.034-10%0.987-5%
Pb Ratio6.041+12%5.3365.3360%4.031+32%7.054-24%7.370-28%
Pe Ratio127.960+12%113.037113.0370%312.824-64%472.010-76%565.574-80%
Price Per Share373.000+12%329.500329.5000%183.000+80%255.000+29%168.180+96%
Price To Free Cash Flow Ratio-120.322-13%-106.290-106.2900%-55.916-47%-94.446-11%-164.217+54%
Price To Total Gains Ratio22.818+12%20.15720.1570%37.930-47%51.453-61%63.474-68%
Quick Ratio--7.1717.1710%2.601+176%4.731+52%4.576+57%
Return On Assets--0.0420.0420%0.011+293%0.006+660%0.011+285%
Return On Equity--0.0470.0470%0.013+266%0.006+647%0.012+289%
Total Gains Per Share--16.34716.3470%4.825+239%8.964+82%5.891+177%
Usd Book Value--177777113.000177777113.0000%130714430.400+36%114188085.640+56%72835682.020+144%
Usd Book Value Change Per Share--1.4941.4940%0.420+256%0.815+83%0.536+179%
Usd Book Value Per Share--5.6445.6440%4.150+36%3.625+56%2.312+144%
Usd Dividend Per Share----0%0.021-100%0.004-100%0.002-100%
Usd Eps--0.2660.2660%0.053+398%0.046+477%0.032+743%
Usd Free Cash Flow---8925118.600-8925118.6000%-9422426.000+6%-8006694.840-10%-4689989.920-47%
Usd Free Cash Flow Per Share---0.283-0.2830%-0.299+6%-0.254-10%-0.149-47%
Usd Free Cash Flow To Equity Per Share--0.9310.9310%-0.319+134%0.416+124%0.263+254%
Usd Market Cap1073887253.900+12%948648391.850948648391.8500%526866936.900+80%734158846.500+29%484199352.174+96%
Usd Price Per Share34.092+12%30.11630.1160%16.726+80%23.307+29%15.372+96%
Usd Profit--8392348.0008392348.0000%1684227.800+398%1455142.840+477%995510.520+743%
Usd Revenue--54615338.80054615338.8000%37957688.800+44%30562679.320+79%21490452.420+154%
Usd Total Gains Per Share--1.4941.4940%0.441+239%0.819+82%0.538+177%
 EOD+5 -3MRQTTM+0 -0YOY+31 -55Y+29 -710Y+26 -10

3.2. Fundamental Score

Let's check the fundamental score of Xvivo Perfusion AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15127.960
Price to Book Ratio (EOD)Between0-16.041
Net Profit Margin (MRQ)Greater than00.154
Operating Margin (MRQ)Greater than00.064
Quick Ratio (MRQ)Greater than17.171
Current Ratio (MRQ)Greater than16.145
Debt to Asset Ratio (MRQ)Less than10.114
Debt to Equity Ratio (MRQ)Less than10.129
Return on Equity (MRQ)Greater than0.150.047
Return on Assets (MRQ)Greater than0.050.042
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Xvivo Perfusion AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.648
Ma 20Greater thanMa 50310.275
Ma 50Greater thanMa 100288.660
Ma 100Greater thanMa 200295.600
OpenGreater thanClose361.500
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Total Other Income Expense Net -343-22,607-22,95022,633-317-550-86756,88256,015



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets2,195,611
Total Liabilities250,566
Total Stockholder Equity1,945,045
 As reported
Total Liabilities 250,566
Total Stockholder Equity+ 1,945,045
Total Assets = 2,195,611

Assets

Total Assets2,195,611
Total Current Assets826,405
Long-term Assets1,369,206
Total Current Assets
Cash And Cash Equivalents 246,088
Short-term Investments 300,000
Net Receivables 118,372
Inventory 141,604
Other Current Assets 20,341
Total Current Assets  (as reported)826,405
Total Current Assets  (calculated)826,405
+/-0
Long-term Assets
Property Plant Equipment 97,552
Goodwill 591,392
Intangible Assets 628,967
Long-term Assets  (as reported)1,369,206
Long-term Assets  (calculated)1,317,911
+/- 51,295

Liabilities & Shareholders' Equity

Total Current Liabilities134,488
Long-term Liabilities116,078
Total Stockholder Equity1,945,045
Total Current Liabilities
Short-term Debt 10,268
Accounts payable 36,053
Other Current Liabilities 84,473
Total Current Liabilities  (as reported)134,488
Total Current Liabilities  (calculated)130,794
+/- 3,694
Long-term Liabilities
Capital Lease Obligations 31,437
Long-term Liabilities Other 64,415
Long-term Liabilities  (as reported)116,078
Long-term Liabilities  (calculated)95,852
+/- 20,226
Total Stockholder Equity
Common Stock805
Retained Earnings 119,573
Accumulated Other Comprehensive Income 60,885
Other Stockholders Equity 1,763,782
Total Stockholder Equity (as reported)1,945,045
Total Stockholder Equity (calculated)1,945,045
+/-0
Other
Capital Stock805
Cash and Short Term Investments 546,088
Common Stock Shares Outstanding 29,935
Current Deferred Revenue3,694
Liabilities and Stockholders Equity 2,195,611
Net Debt -214,651
Net Invested Capital 1,945,045
Net Working Capital 691,917
Property Plant and Equipment Gross 167,678
Short Long Term Debt Total 31,437



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-31
> Total Assets 
140,875
114,518
127,565
201,701
204,180
349,298
538,540
586,612
634,487
1,150,309
1,542,596
1,733,084
2,195,611
2,195,6111,733,0841,542,5961,150,309634,487586,612538,540349,298204,180201,701127,565114,518140,875
   > Total Current Assets 
0
32,288
33,021
93,142
95,635
98,106
264,622
277,680
259,885
463,230
547,532
467,508
826,405
826,405467,508547,532463,230259,885277,680264,62298,10695,63593,14233,02132,2880
       Cash And Cash Equivalents 
2,377
7,776
4,131
48,203
41,034
23,371
195,022
186,264
159,146
353,436
398,696
246,545
246,088
246,088246,545398,696353,436159,146186,264195,02223,37141,03448,2034,1317,7762,377
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
300,000
300,000000000000000
       Net Receivables 
75,057
11,137
8,698
13,552
20,984
37,803
30,772
46,925
49,110
43,700
63,911
104,259
118,372
118,372104,25963,91143,70049,11046,92530,77237,80320,98413,5528,69811,13775,057
       Other Current Assets 
816
1
10,900
18,749
26,003
2,381
38,897
55,029
6,958
5,943
7,335
10,138
20,341
20,34110,1387,3355,9436,95855,02938,8972,38126,00318,74910,9001816
   > Long-term Assets 
0
82,230
94,544
108,559
108,545
251,192
273,918
308,932
374,602
687,079
995,064
1,265,576
1,369,206
1,369,2061,265,576995,064687,079374,602308,932273,918251,192108,545108,55994,54482,2300
       Property Plant Equipment 
92
748
917
1,124
7,123
15,166
16,277
15,615
23,554
21,334
26,297
47,579
97,552
97,55247,57926,29721,33423,55415,61516,27715,1667,1231,12491774892
       Goodwill 
0
3,811
3,008
2,206
3,849
65,672
65,273
65,614
65,773
223,938
460,228
625,319
591,392
591,392625,319460,228223,93865,77365,61465,27365,6723,8492,2063,0083,8110
       Long Term Investments 
0
0
0
0
0
0
71
71
223
0
0
0
0
00002237171000000
       Intangible Assets 
1,465
75,174
86,214
97,135
93,086
158,072
176,902
214,084
272,736
400,718
465,209
552,995
628,967
628,967552,995465,209400,718272,736214,084176,902158,07293,08697,13586,21475,1741,465
       Long-term Assets Other 
0
522
2,784
3,176
0
1
71
71
223
1
1,159
411
628,967
628,9674111,15912237171103,1762,7845220
> Total Liabilities 
128,967
25,753
30,930
25,518
19,306
32,884
34,208
46,135
56,966
141,848
257,146
302,948
250,566
250,566302,948257,146141,84856,96646,13534,20832,88419,30625,51830,93025,753128,967
   > Total Current Liabilities 
124,942
23,721
25,658
18,758
15,581
29,840
30,896
42,573
52,599
72,248
104,519
134,896
134,488
134,488134,896104,51972,24852,59942,57330,89629,84015,58118,75825,65823,721124,942
       Short-term Debt 
0
9,089
6,659
0
0
0
0
0
3,396
3,926
4,199
5,550
10,268
10,2685,5504,1993,9263,396000006,6599,0890
       Short Long Term Debt 
0
0
6,659
0
0
0
0
0
0
0
0
0
0
00000000006,65900
       Accounts payable 
1,335
6,700
8,419
6,468
3,650
12,563
11,121
16,333
14,406
14,468
21,445
38,469
36,053
36,05338,46921,44514,46814,40616,33311,12112,5633,6506,4688,4196,7001,335
       Other Current Liabilities 
123,607
317
458
12,290
11,931
17,277
19,775
26,240
3,543
4,954
31,618
87,708
84,473
84,47387,70831,6184,9543,54326,24019,77517,27711,93112,290458317123,607
   > Long-term Liabilities 
0
2,032
5,272
6,760
3,725
3,044
3,312
3,562
4,367
69,600
152,627
168,052
116,078
116,078168,052152,62769,6004,3673,5623,3123,0443,7256,7605,2722,0320
       Long term Debt Total 
0
0
0
0
0
0
0
0
2,154
3,286
1,522
4,455
0
04,4551,5223,2862,15400000000
       Capital Lease Obligations Min Short Term Debt
0
-9,089
-6,659
0
0
0
0
0
2,154
3,286
1,522
4,455
21,169
21,1694,4551,5223,2862,15400000-6,659-9,0890
       Long-term Liabilities Other 
0
0
0
0
0
-269
0
0
0
40,150
124,522
137,130
64,415
64,415137,130124,52240,150000-26900000
       Deferred Long Term Liability 
0
0
84,904
95,908
91,797
155,169
173,430
210,460
266,517
393,969
456,551
544,510
0
0544,510456,551393,969266,517210,460173,430155,16991,79795,90884,90400
> Total Stockholder Equity
11,908
88,765
96,635
176,183
184,874
316,414
504,332
540,477
577,521
1,008,461
1,285,450
1,430,136
1,945,045
1,945,0451,430,1361,285,4501,008,461577,521540,477504,332316,414184,874176,18396,63588,76511,908
   Common Stock
100
500
500
550
550
604
670
675
680
734
754
762
805
805762754734680675670604550550500500100
   Retained Earnings 
11,808
83,340
89,689
12,444
20,617
21,579
27,383
39,921
44,860
1,125
9,277
27,753
119,573
119,57327,7539,2771,12544,86039,92127,38321,57920,61712,44489,68983,34011,808
   Capital Surplus 
0
0
0
0
0
280,890
467,661
486,860
515,753
1,006,784
1,253,330
1,313,839
0
01,313,8391,253,3301,006,784515,753486,860467,661280,89000000
   Treasury Stock0000000000000
   Other Stockholders Equity 
0
4,925
6,446
163,189
163,707
294,231
476,279
499,881
515,753
1,006,602
1,253,330
1,313,839
1,763,782
1,763,7821,313,8391,253,3301,006,602515,753499,881476,279294,231163,707163,1896,4464,9250



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue597,542
Cost of Revenue-180,629
Gross Profit416,913416,913
 
Operating Income (+$)
Gross Profit416,913
Operating Expense-378,407
Operating Income38,50638,506
 
Operating Expense (+$)
Research Development129,252
Selling General Administrative76,944
Selling And Marketing Expenses232,261
Operating Expense378,407438,457
 
Net Interest Income (+$)
Interest Income8,850
Interest Expense-1,190
Other Finance Cost-13,441
Net Interest Income-5,781
 
Pretax Income (+$)
Operating Income38,506
Net Interest Income-5,781
Other Non-Operating Income Expenses0
Income Before Tax (EBT)94,521-17,509
EBIT - interestExpense = 37,316
94,521
93,010
Interest Expense1,190
Earnings Before Interest and Taxes (EBIT)38,50695,711
Earnings Before Interest and Taxes (EBITDA)69,369
 
After tax Income (+$)
Income Before Tax94,521
Tax Provision-7,630
Net Income From Continuing Ops24,08086,891
Net Income91,820
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses559,036
Total Other Income/Expenses Net56,0155,781
 

Technical Analysis of Xvivo Perfusion AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xvivo Perfusion AB. The general trend of Xvivo Perfusion AB is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xvivo Perfusion AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Xvivo Perfusion AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: .

The bearish price targets are: 343.50 > 338.50 > 294.00.

Tweet this
Xvivo Perfusion AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Xvivo Perfusion AB. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Xvivo Perfusion AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Xvivo Perfusion AB. The current macd is 19.92.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xvivo Perfusion AB price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Xvivo Perfusion AB. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Xvivo Perfusion AB price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Xvivo Perfusion AB Daily Moving Average Convergence/Divergence (MACD) ChartXvivo Perfusion AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Xvivo Perfusion AB. The current adx is 34.81.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Xvivo Perfusion AB shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Xvivo Perfusion AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Xvivo Perfusion AB. The current sar is 320.88.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Xvivo Perfusion AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Xvivo Perfusion AB. The current rsi is 73.65. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Xvivo Perfusion AB Daily Relative Strength Index (RSI) ChartXvivo Perfusion AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Xvivo Perfusion AB. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xvivo Perfusion AB price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Xvivo Perfusion AB Daily Stochastic Oscillator ChartXvivo Perfusion AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Xvivo Perfusion AB. The current cci is 149.36.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Xvivo Perfusion AB Daily Commodity Channel Index (CCI) ChartXvivo Perfusion AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Xvivo Perfusion AB. The current cmo is 52.46.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Xvivo Perfusion AB Daily Chande Momentum Oscillator (CMO) ChartXvivo Perfusion AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Xvivo Perfusion AB. The current willr is -5.52763819.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Xvivo Perfusion AB Daily Williams %R ChartXvivo Perfusion AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Xvivo Perfusion AB.

Xvivo Perfusion AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Xvivo Perfusion AB. The current atr is 16.08.

Xvivo Perfusion AB Daily Average True Range (ATR) ChartXvivo Perfusion AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Xvivo Perfusion AB. The current obv is 2,107,380.

Xvivo Perfusion AB Daily On-Balance Volume (OBV) ChartXvivo Perfusion AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Xvivo Perfusion AB. The current mfi is 71.89.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Xvivo Perfusion AB Daily Money Flow Index (MFI) ChartXvivo Perfusion AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Xvivo Perfusion AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-16RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Xvivo Perfusion AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Xvivo Perfusion AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.648
Ma 20Greater thanMa 50310.275
Ma 50Greater thanMa 100288.660
Ma 100Greater thanMa 200295.600
OpenGreater thanClose361.500
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Xvivo Perfusion AB with someone you think should read this too:
  • Are you bullish or bearish on Xvivo Perfusion AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xvivo Perfusion AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Xvivo Perfusion AB

I send you an email if I find something interesting about Xvivo Perfusion AB.


Comments

How you think about this?

Leave a comment

Stay informed about Xvivo Perfusion AB.

Receive notifications about Xvivo Perfusion AB in your mailbox!